Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2003-01-15
2009-06-02
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S093200, C424S093480
Reexamination Certificate
active
07541043
ABSTRACT:
Compositions and methods for protecting a susceptable host against an infection ofShigella sonneiare disclosed. Such compositions and methods are useful for protecting the host against bacillary dysentery and shigellosis.
REFERENCES:
patent: 4632830 (1986-12-01), Formal et al.
patent: 5672345 (1997-09-01), Curtiss, III
patent: 5980907 (1999-11-01), Dougan et al.
patent: 6190669 (2001-02-01), Noriega et al.
Keren et al. (Infect. Immun., 37:387-389, 1982).
Viret et al. (Mol. Microbiol., 7:239-252, 1993).
Bowie et al. (Science, 1990, 247:1306-1310).
Burgess et al. (J. of Cell Bio. 111:2129-2138, 1990).
Lazar et al. (Molecular and Cellular Biology, 1988, 8:1247-1252).
Xu et al. (Abstract B-436, Abstracts of the 101st General Meeting of the American Society for Microbiology, May 2001).
Galan et al. (Gene, 94:29-35, 1990).
Belanger et al., “Functional analysis of genes responsible for the synthesis of the B- band O antigen ofPseudomonas aeruginosa serotype O6 lipopolysaccharide”,. Microbiology. 145:3505-3521 (1999).
Bilge et al., “Role of theEscherichia coliO157:H7 O side chain in adherence and analysis of an rfb locus”, Infect Immun. 64:4795-4801 (1996).
Black et al., “Prevention of shigellosis by aSalmonella typhi-Shigella sonneibivalent vaccine”, J Infect Dis. 155:1260-1265 (1987).
Burrows et al., “Functional conservation of the polysaccharide biosynthetic protein WbpM and its homologues inPseudomonas aeruginosaand other medically significant bacteria” Infect Immun. 68:931-936 (2000).
Chida et al., “The complest DNA sequence of the O antigen gene region ofPlesiomonas shigelloidesserotype O17 which is identical toShigella sonneiform I antigen”, Microbiol Immunol. 44:161-172 (2000).
Creuzenet et al., “FIaA1, a new bifunctional UDP-GlcNAc C6 dehydratase / C4 reductase fromHelicobacter pylon”, J Biol Chem. 275:34873-34880 (2000).
DuPont et al., “Immunity in shigellosis. I. Response of man to attenuated straines ofShigella” J Infect Dis. 125:5-11 (1972).
Ertesvag et al., “Cloning and expression of anAzotobacter vinelandiimannuronan C-5- epimerase gene”, J Bacteriol. 176:2846-2853 (1994).
Formal et al., “Construction of a potential bivalent vaccine strain: Introduction ofShigella sonneiform I antigen genes into the gaIESalmonella typhiTy21a typhoid vaccine strain”, Infect Immun. 34:746-750.
Franklin et al., “Pseudomonas aeruginosaAIgG is a polymer level alginate C5-mannuronan epimerase”, J Bacteriol. 176:1821-30 (1994).
Germanier et al., “Isolation and characterization of GaI E mutant Ty 21a ofSalmonella typhi:a candidate strain for a live, oral typhoid vaccine”, J Infect Dis. 131:553-558 (1975).
Gotschlich, “Genetic locus for the biosynthesis of the variable portion ofNeisseria gonorrhoeaelipooligosaccharide”, J Exp Med. 180:2181-2190 (1994).
Hartman et al., “Molecular analysis of variant plasmid forms of a bivalentSalmonella typhi-Shigella sonneivaccine strain” J. Clin. Microbiol. 29:27-32 (1991).
Hartman et al., “Construction of a stable attenuatedShigella sonneiDeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model”, Infect Immun. 66:4572-4576 (1998).
Hashimoto et al., “Complete nucleotide sequence and molecular characterization of ViaB region encoding Vi antigen inSalmonella typhi”, J Bacteriol. 175:4456-4465 (1993).
Heinrichs et al., “The assembly system for the lipopolysaccharide R2 core-type ofEscherichia coliis a hybrid of those found inEscherichia coliK-12 andSalmonella enterica. Structure and function of the R2 WaaK and WaaL homologs”, J Biol Chem. 273:8849-8859 (1998).
Herrington et al., “Studies in volunteers to evaluate candidateShigellavaccines: further experience with a bivalentSalmonella typhi-Shigella sonneivaccine and protection conferred by previousShigella sonneidisease”, Vaccine. 8:353-357 (1990).
Kenne et al., “Structural studies of the O-specific side-chains of theShigella sonneiphase I lipopolysaccharide”, Carbohydr. Res. 78:119-126 (1980).
Kopecko et al., “Genetic and physical evidence for plasmid control ofShigella sonneiform I cell surface antigen”, Infect Immun. 29:207-214 (1980).
Li et al. “Biosynthesis of heparin/heparan sulfate. cDNA cloning and expression of D-glucuronyl C5-epimerase from bovine lung”, J Biol Chem. 272:28158-28163 (1997).
Paulsen et al., “A family of gram-negative bacterial outer membrane factors that function in the export of proteins, carbohydrates, drugs and heavy metals from gram-negative bacteria”, FEMS Microbiol Lett. 156:1-8 (1997).
Sansonetti et al., “Shigella sonneiplasmids: evidence that a large plasmid is necessary for virulence”, Infect Immun. 34:75-83 (1981).
Seid et al., “Unusual lipopolysaccharide antigens of aSalmonella typhioral vaccine strain expressing theShigella sonneiform I antigen”, J Biol Chem. 259:9028-9034 (1984).
Shepherd et al., “Comparison of O-antigen gene clusters ofEscherichia coli(Shigella)sonneiandPlesiomonas shigelloidesO17: sonnei gained its current plasmid-borne O-antigen genes fromP. shigelloidesin a recent event”, Infect Immun. 68:6056-6061 (2000).
Stroeher et al., “A putative pathway for perosamine biosynthesis is the first function encoded within the rfb region ofVibrio choleraeO1”. Gene. 166:33-42 (1995).
Van de Verg et al., “Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalentSalmonella typhi-Shigella sonneivaccine or infection by pathogenicS. sonnei.” Infect Immun. 58:2002-2004 (1990).
Viret et al., “Molecular cloning and characterization of the genetic determinants that express the completeShigellaserotype D (Shigella sonnei) lipopolysaccharide in heterologous live attenuated vaccine strains”, Mol Microbiol. 7:239-252 (1993).
Wang et al., “Expression of the O antigen gene cluster is regulated by RfaH through the JUMPstart sequence. FEMS”, Microbiol Lett. 165:201-206 (1998).
Whitfield et al., “Structure, assembly and regulation of expression of capsules inEscherichia coli. Mol” Microbiol. 31:1307-1319 (1999).
Yoshida et al., “Molecular cloning and characterization of form I antigen genes ofShigella sonnei”, J Gen Microbiol. 137:867-874 (1991).
Zhao et al., “WbpO, a UDP-N-Acetyl-D-galactosamine dehydrogenase fromPseudomonas aeruginosaserotype O6”, J Biol Chem. 275:33252-33259 (2000).
Cisar John O.
Kopecko Dennis J.
Xu De-Qi
Gangle Brian J
Knobbe Martens Olson & Bear LLP
Navarro Mark
The United States of America as represented by the Department of
LandOfFree
Vaccine for protection against Shigella sonnei disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine for protection against Shigella sonnei disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine for protection against Shigella sonnei disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4093547